TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Phase 3 study of the experimental drug obicetrapib found lower blood levels of the Alzheimer’s biomarker pTau-217 in a subgroup of participants carrying the ApoE4 risk gene. That finding does not show that the drug prevents Alzheimer’s or improves cognition; a separate Phase 2b trial is now testing biomarker effects in people with disease hallmarks but no symptoms.
Obicetrapib, an experimental cholesterol-lowering drug, reduced blood levels of the Alzheimer’s biomarker pTau-217 in a subgroup of people carrying the ApoE4 risk gene, according to findings described by Being Patient. The result is a biomarker signal, not evidence that the drug prevents Alzheimer’s or treats memory and thinking problems; NewAmsterdam Pharma has begun enrolling participants in a separate Phase 2b trial to examine that question further.
The reported Phase 3 study tested obicetrapib in people with heart disease or a genetic form of high cholesterol. In a subgroup of 1,727 ApoE4 carriers, the drug lowered blood pTau-217, a marker used to help diagnose Alzheimer’s in people with cognitive impairment. The source report does not provide the size of the biomarker change or say that participants experienced cognitive improvement.
Obicetrapib belongs to a class called CETP inhibitors. It works by limiting the transfer of cholesterol into low-density lipoprotein, or LDL. NewAmsterdam Pharma has enrolled the first participant in a Phase 2b Alzheimer’s trial. The study is designed to test whether a year of treatment can lower Alzheimer’s biomarkers in people who have signs of the disease but no symptoms.
Evidence about statins, the widely used cholesterol-lowering medicines, is mixed. An observational study of more than 130,000 people with Type 2 diabetes in Denmark reported dementia risk reductions of 15% among those who started statins early and 10% among those who started later, over a decade. Those associations do not establish that statins caused the lower risk. Earlier randomized trials did not show that statins treated cognitive decline, and a trial in healthy adults over 70 did not find a dementia-prevention effect.
Biomarker Changes Need Cognitive Tests
The findings draw attention to whether cholesterol pathways could affect Alzheimer’s biology, but a change in a blood marker is not the same as a change in disease symptoms or outcomes. pTau-217 is a biomarker; the reported result does not show that participants thought more clearly, avoided dementia, or had less brain disease.
That distinction matters for patients and clinicians considering cholesterol medicines. Statins are used to reduce cardiovascular risk, but the evidence supplied here does not support taking them specifically to prevent or treat Alzheimer’s. Obicetrapib’s potential role also remains experimental. The next trial’s biomarker results may inform further research, but evidence of clinical benefit would require studies measuring cognition and other meaningful outcomes.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
As an affiliate, we earn on qualifying purchases.
Why Statin Evidence Remains Mixed
Cholesterol in the blood and cholesterol in the brain are not interchangeable. The source report explains that cholesterol molecules in the blood do not cross into the brain, while researchers are investigating whether abnormal cholesterol processing within the brain contributes to Alzheimer’s. Statins lower blood cholesterol and do not readily reach the brain, a distinction that informs some experts’ skepticism about their direct effect on Alzheimer’s.
Observational findings can identify patterns but cannot rule out differences between people who take a medicine and those who do not. Mayo Clinic neurologist David Knopman told Being Patient that statin users may be more medically informed and more likely to follow healthy behaviors, complicating comparisons. Randomized trials are better suited to testing cause and effect, but long studies of dementia prevention can be costly. Knopman said a long-term statin prevention trial may not be realistic, in part because the drugs are off-patent.
“I’m of the opinion that our traditional way of treating cholesterol with statins is probably not going to work.”
— Dr. Heather Ferris, University of Virginia clinical endocrinologist and scientist, speaking to Being Patient
What the Biomarker Result Cannot Show
The reported result does not establish whether obicetrapib changes Alzheimer’s symptoms, delays disease, or prevents dementia. The source report gives no numerical size for the pTau-217 reduction and does not describe a cognitive benefit. It also does not establish whether the result applies beyond the ApoE4 subgroup or to people with Alzheimer’s at different stages.
The Danish statin study found an association, not proof of cause and effect, and its population had Type 2 diabetes. Earlier randomized studies cited by Being Patient did not demonstrate cognitive benefit from statins. The available information also does not say when the Phase 2b trial will report results or whether its findings would lead to a larger trial.
Results From the Phase 2b Trial
The immediate next step is the Phase 2b trial of obicetrapib, which is testing whether one year of treatment changes Alzheimer’s biomarkers in people with disease hallmarks but no symptoms. Its findings could clarify whether the Phase 3 subgroup signal is repeatable in a group selected for Alzheimer’s-related features.
Even a further biomarker reduction would not by itself establish prevention or treatment. Researchers would need evidence about cognitive function and clinical outcomes, and the source report does not provide a timetable for those results. For now, the report describes a reason to investigate the cholesterol-Alzheimer’s link, not a new recommended Alzheimer’s treatment.
Key Questions
Does lowering cholesterol prevent Alzheimer’s?
The evidence described here does not show that cholesterol-lowering medicines prevent Alzheimer’s. One observational statin study found lower dementia risk among people with Type 2 diabetes who started treatment earlier, but that association cannot prove the medicine caused the difference.
Did obicetrapib improve memory or thinking?
No cognitive improvement was reported. The Phase 3 finding was a reduction in blood pTau-217 among a subgroup of ApoE4 carriers; the report does not say that participants’ memory or thinking improved.
What is the Phase 2b Alzheimer’s trial testing?
NewAmsterdam Pharma’s trial is testing whether a year of obicetrapib treatment lowers Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. The source report does not give an expected results date.
Should someone take a statin to prevent Alzheimer’s?
The findings described here do not establish statins as Alzheimer’s prevention or treatment. Decisions about cholesterol medicines should be made with a qualified health professional based on an individual’s medical needs.
Source: rss
